Open For Enrollment

Current Research Studies

Nephrotex Research Group, a division of Texas Kidney Institute, currently has the following clinical trials open for recruitment. If you are interested in seeing if you may qualify for a study, you may contact Elisha Shelton, Clinical Research Manager, at 214-253-8955 for more information.


The Janus TM Study is looking at a potential new medication (an investigational medication) for people with immunoglobuin A Nephropathy (IgAN). The study will look at how safe the investigational medication is and how well it works to decrease the number of antibodies (IgA) that collect in the kidneys of patient with IgAN causing inflammation, which affects how the kidneys work. You may be able to take part in the JANUS Study if you: are 18 years of age or older; have IgAN, as demonstrated on renal biopsy in the past 5 years. The study will last about 2 years. During the study, you will be in regular contact with the study doctor who will monitor your kidney function. All study-related medications and assessments will be provided at no cost.

We are looking for adults 18 years of age and older who have been diagnosed with FSGS to take part in a clinical research study. The purpose of the study is to determine whether H.P. Acthar* Gel (repository corticotropin injection) is helpful for adult patients with FSGS who still have an abnormal amount of protein in their urine, despite prior treatment. Individuals will be evaluated to determine their eligibility to participate in the study. Each patient who qualifies will receive the study drug, study-related procedures, and laboratory tests at no cost. Reimbursement for reasonable time and travel costs may also be available.

There are currently no FDA approved treatments for lupus nephritis; however several promising studies looking at potential treatments are underway. Aurinia Pharmaceuticals, a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious disease with a high unmet medical need, initiated a new study that is accepting eligible participants. The study, called Aurora, is evaluating an investigational drug, voclosporin, for the treatment of lupus nephritis. Approximately 324 participants with biopsy confirmed lupus nephritis will be enrolled in this study at multiple sites around the world. You may qualify for the Aurora study if you: have not had a kidney transplant; are not on renal dialysis; are currently taking corticosteroids; have a diagnosis of systemic lupus erythematosus; are spilling protein in your urine and have had a previous kidney biopsy

In Alport syndrome, a type of building block protein (called Type IV collagen) does not work properly in the body due to an inherited genetic defect. Because of this, there is a slow decreased in how well the kidneys work. People eventually develop kidney failure (know as end-stage renal disease) requiring dialysis therapy or a kidney transplant. There is an urgent need for research into new therapies that can preserve kidney function and delay dialysis therapy for people with Alport Syndrome. The HERA study is a clinical trial looking at an investigational drug which is a drug that has not yet been approved by healthy authorities for doctors to prescribe. This study has been designed to evaluate the safety and effectiveness of the investigational drug in people with Alport syndrome. In this study, it is being compared to a placebo (which looks like the investigational drug, but contains no active medicine). The investigational drug is a targeted therapy. It is aimed to target small genetic building blocks that are important in regulating gene activity. Researchers are studying whether the investigational drug could help preserve kidney function in patient’s with Alport syndrome. Who can take part in the study? Approximately 40 male participants with Alport syndrome will take part in the HERA Study. The HERA study is looing for male participants who: are 18-6 years of age (inclusive). .The minimum age may be lowered to 12 years old after successful safety review of the first 10 adult patients; have a confirmed diagnosis of Alport syndrome; have not received a kidney transplant; and are currently not on dialysis.

Get Started Today

Do you have questions about kidney disease? Reach out today to get started or get in touch with one of our friendly team members who will help you begin the road to healing.

Schedule Appointment Call: (214) 396-4950